To incorporate the microenvironment component in the prognosis algorithms, the Lunenburg Lymphoma Biomarker Consortium studied a homogeneously rituximab-chemotherapy-treated group of FL patients and found that low CD8+ T-cell percentages, the presence of CD163-expressing macrophages, EZH2 wild-type (WT) status and gain of chromosome 18 in the diagnostic tumor biopsies predict a poor prognosis in FL treated with R-CHOP (Stevens et al., 2017), pointing to an overall negative impact of macrophages in the outcome of FL patients in these conditions. The gene discussed is EZH2; the disease is lymphoma.